What I don't understand about 42 day and 60 day data is weather they go beyond the 2 dose limit in the protocol? Have we figured this out? Also, If the DSMB said no changes and only wanted to see 42 day data at 75% enrollment, why would we think they are looking beyond 28days with full enrollment? I still feel the trial as designed generated good PE data and the 2-3 week timeline is enough for manufacturing/labeling/distribution discussions and not about the PE.